Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03464916 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
A Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Sorrento Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT03464916: Completed Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Sorrento Therapeutics.
NCT03464916 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma that has completed, run by Sorrento Therapeutics. The registered enrollment target is 10 participants, below the 341-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03464916, a Phase 1 study of Relapsed or Refractory Multiple Myeloma, has completed, sponsored by Sorrento Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study is an open-label Phase 1 single dose-escalation safety study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma, who meet all other eligibility criteria.
Primary Outcome
The MTD is assessed according to a 3+3 dose-escalation design by the occurrence of treatment-emergent dose-limiting toxicities during the 28-day Treatment Period in the dose-escalation phase of the study
Conditions Studied
Interventions
- BIOLOGICAL CAR2 Anti-CD38 A2 CAR-T Cells
Study Locations (4)
Florida
- Mayo Clinic Florida - Jacksonville
Minnesota
- Mayo Clinic Minnesota - Rochester
New York
- Icahn School of Medicine - New York
Pennsylvania
- University of Pennsylvania, Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2022-02-28 |
| Phase | Phase 1 |
What the finished NCT03464916 record still lists
NCT03464916 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 341-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which CAR2 Anti-CD38 A2 CAR-T Cells is the first listed.
NCT03464916 reports a single indexed study location in Florida, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT03464916 about?
NCT03464916 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients". The study is an open-label Phase 1 single dose-escalation safety study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma, who meet all other eligibility criteria.
What is the current status of trial NCT03464916?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2018-10-15. Estimated completion is 2022-02-28.
What conditions does trial NCT03464916 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT03464916?
The interventions under investigation include: CAR2 Anti-CD38 A2 CAR-T Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03464916?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03464916 being conducted?
This trial has 4 study locations across Florida, Minnesota, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03464916's enrollment target sits among peer trials
10 10th of 10 higher than 1 of 10 other Relapsed or Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed or Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
-
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
COMPLETED · Phase 1
-
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI